GlassScriptPhysician profile
Lauren Elizabeth Downey
NPI 1063075976
$19,412.41
in general payments reported to CMS, 2019-2025
42 companies · $4,700 in 2025
The $4,700 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,257 · 2022: $3,801 · 2023: $3,957 · 2024: $4,698 · 2025: $4,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $15.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,338.81 |
| Education | $15.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,996.91 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,626.86 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,507.08 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,466.35 | 2022-2025 | Stelara, Tremfya |
| Ironwood Pharmaceuticals, INC | $1,295.93 | 2021-2025 | Linzess |
| Ardelyx, INC. | $1,245.17 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $661.40 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $639.35 | 2022-2025 | |
| Madrigal Pharmaceuticals | $556.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $526.63 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $514.59 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $484.69 | 2021-2025 | Gimoti |
| Celgene Corporation | $463.93 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $449.54 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $418.20 | 2021-2024 | Dificid |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $413.15 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $367.84 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $352.46 | 2023-2025 | Omvoh |
| Redhill Biopharma INC. | $350.97 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Aimmune Therapeutics, INC. | $321.81 | 2024-2025 | Zenpep |
| Janssen Scientific Affairs, LLC | $195.38 | 2023-2025 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $183.10 | 2023-2025 | Iqirvo, Bylvay |
| Intra-Sana Laboratories | $159.40 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $154.87 | 2021-2024 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $150.28 | 2021-2023 | |
| Convatec INC. | $125.13 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.54 | 2025 | |
| Lucid Diagnostics INC. | $112.75 | 2024 | |
| Ferring Pharmaceuticals INC. | $111.80 | 2023-2025 | Rebyota, Cimzia |
| Braintree Laboratories, INC. | $108.28 | 2021-2025 | Sutab, Suflave |
| Daiichi Sankyo INC. | $58.21 | 2022 | |
| Organon LLC | $39.79 | 2023-2024 | Renflexis |
| Alexion Pharmaceuticals, INC. | $38.87 | 2022 | |
| Celltrion USA INC. | $36.87 | 2024 | Zymfentra |
| Fresenius Kabi USA, LLC | $34.19 | 2023-2024 | Idacio |
| Enterra Medical, INC. | $26.80 | 2024 | |
| Pharmacosmos Therapeutics INC. | $18.79 | 2024 | Monoferric |
| Shield Therapeutics INC | $17.97 | 2023 | Accrufer |
| Novo Nordisk INC | $15.89 | 2025 | Wegovy |
| Boston Scientific Corporation | $15.59 | 2022 | |
| Amgen INC. | $14.31 | 2021 | |
| Alfasigma USA, INC. | $14.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Downey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.